Simvastatin-ratiopharm® ( DrugBank: Simvastatin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 162 | Pemphigoid | 1 |
162. Pemphigoid
Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-004361-32-DE (EUCTR) | 26/02/2013 | 22/05/2012 | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidA prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEM | Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Simvastatin-ratiopharm® Product Name: Simvastatin-ratiopharm Other descriptive name: SIMVASTATIN | Philipps-Universität Marburg | NULL | Not Recruiting | Female: yes Male: yes | Germany |